Jump to content

Pontiano Kaleebu

From Wikipedia, the free encyclopedia

Pontiano Kaleebu
Born1960 (age 63–64)
Uganda
NationalityUgandan
CitizenshipUganda
Alma materMakerere University
(Bachelor of Medicine and Bachelor of Surgery)
University of London
(Diploma in Immunology)
(Doctor of PhilosophyinImmunology)
Occupation(s)Physician, Academic
Clinical Immunologist
HIV/AIDS Researcher
and Medical Administrator
Years active1995 – present
Known forProfessional competence
TitleExecutive DirectorofUganda Virus Research Institute

Pontiano Kaleebuis a Ugandanphysician,clinical immunologist,HIV/AIDS researcher,academicandmedical administrator,who is theexecutive directorof theUganda Virus Research Institute.[1]

He also concurrently serves as the director of the joint clinical research unit owned by theMedical Research Council (United Kingdom),the Uganda Virus Research Institute, and theLondon School of Hygiene & Tropical Medicine,located inEntebbe,Uganda, carrying on research in infectious, non-communicable and neglected diseases.[1][2]

Background and education

[edit]

Pontiano Kaleebu was born in Uganda, circa 1960.[3]He attended Jinja Kaloli Primary School, inWakiso District,where he obtained hisPrimary Leaving Certificate.He then transferred toSt. Mary's College Kisubi,where he undertook his O-Level studies. He completed his A-Level education atKampala High School,where he obtained hisHigh School Diploma.[3]

He was admitted toMakerere University School of Medicine,where he graduated with aBachelor of Medicine and Bachelor of Surgerydegree in the mid 1980s. He interned atSt. Francis Hospital Nsambya,under Dr. Merriam Duggan.[3]

In 1988, Kaleebu was awarded a scholarship to study immunology at theRoyal Postgraduate Medical School,atHammersmith Hospital,inWest London,in the United Kingdom. He graduated with a Diploma in Immunology.[3]

While in London, he was offered the opportunity to pursue a doctorate in immunology, by theUniversity of London,on scholarship, under Professor Jonathan Weber, atSt Mary's Hospital, London.He completed his PhD program in the mid 1990s.[1][3]

Career

[edit]

1987, Kaleebu was recruited as a medical research officer at the Uganda Virus Research Institute, by its director, Dr. Sylvester Sempala. Following the completion of his PhD studies, Kaleebu returned to the institute and was appointed as the head of the immunology department. The following year, he joined the joint research programme at the Medical Research Council and the Uganda Virus Research Institute.[3]

Over the years, Dr Kaleebu has become a leading international researcher in the areas of immunology and virology and is a member to the international team that participated the first vaccine trial in Africa against HIV/AIDS. In the late 2000s, he became the director of the Uganda Virus Research Institute in an acting capacity.[3]He was confirmed in that position in the mid-2010s. He is a Professor of immunovirology at the London School of Hygiene and Tropical Medicine.[4]

Other considerations

[edit]

His main research interests are HIV vaccine research especially understanding HIV diversity and resistance to antiretroviral drugs, as well as the protective immune responses. He is the recipient of numerous Awards including (a) the Scientific Achievement Award fromRotary International,awarded in 2003 (b) the Presidential Science Award 2005/2006 and (c) the Fellowship ofImperial College London,Faculty of Medicine, awarded in 2010 (d) Fellow of the Royal College of Physicians of Edinburgh- FRCP Edin 2016 (e) Fellow of the Academy of Medical Sciences-FMedSci 2020. (f) Fellow of the Uganda National Academy of Science-FUNAS 2021. He has co-authored more than 260 publications in peer reviewed journals.[1]Some of his most cited publications include; Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis (2019),[5]HIV subtype diversity worldwide (2019),[6]Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania (2019),[7]HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis (2018),[8]Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease (2016),[9]Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study (2016),[10]The African genome variation project shapes medical genetics in Africa (2015),[11]Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis (2015),[12]A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia (2015),[13]Towards host-directed therapies for tuberculosis (2015),[14]Randomised controlled trials for Ebola: practical and ethical issues (2014),[15]Immune activation alters cellular and humoral responses to yellow fever 17D vaccine (2014),[16]Pregnancy, parturition and preeclampsia in women of African ancestry (2014),[17]Discovery and refinement of loci associated with lipid levels (2013),[18]Common variants associated with plasma triglycerides and risk for coronary artery disease (2013),[19]Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis (2013),[20]High HIV incidence and socio-behavioral risk patterns in fishing communities on the shores of Lake Victoria, Uganda (2012),[21]HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda (2011),[22]Transmitted HIV type 1 drug resistance among individuals with recent HIV infection in East and Southern Africa (2011),[23]CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa (2009),[24]Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa (2008),[25]Relation between chemokine receptor use, disease stage, and HIV-1 subtypes A and D: results from a rural Ugandan cohort (2007),[26]The glutamine-rich region of the HIV-1 Tat protein is involved in T-cell apoptosis (2004),[27]Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1—positive persons in Uganda (2002),[28]Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort (2001),[29]Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO network for HIV isolation and characterization (1996)[30]

Awards

[edit]

He received a medal of service from the government of the Republic of Uganda.[31]

References

[edit]
  1. ^abcd"Profile of Professor Pontiano Kaleebu".Entebbe:Medical Research Council (Uganda).2018.Retrieved4 December2018.
  2. ^Ainebyoona, Emmanuel (14 May 2018),"UVRI partners with London school for cancer research",Daily Monitor,Kampala,retrieved4 December2018
  3. ^abcdefgKalibbala, Gladys (29 November 2009)."Kaleebu came home to find cure for AIDS".New Vision.Kampala.Retrieved4 December2018.
  4. ^"Meet Prof. Pontiano Kaleebu: UVRI's new Director".Atlanta:International Association of National Public Health Institutes.3 August 2016.Retrieved4 December2018.
  5. ^Hemelaar, Joris; Elangovan, Ramyiadarsini; Yun, Jason; Dickson-Tetteh, Leslie; Fleminger, Isabella; Kirtley, Shona; Williams, Brian; Gouws-Williams, Eleanor; Ghys, Peter D; Abimiku, Alash'le G; Agwale, Simon (1 February 2019)."Global and regional molecular epidemiology of HIV-1, 1990–2015: a systematic review, global survey, and trend analysis".The Lancet Infectious Diseases.19(2): 143–155.doi:10.1016/S1473-3099(18)30647-9.ISSN1473-3099.PMID30509777.S2CID54485664.
  6. ^Bbosa, Nicholas; Kaleebu, Pontiano; Ssemwanga, Deogratius (2019)."HIV subtype diversity worldwide".Current Opinion in HIV and AIDS.14(3): 153–160.doi:10.1097/COH.0000000000000534.ISSN1746-630X.PMID30882484.S2CID81977044.
  7. ^"Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania".The Journal of Infectious Diseases.Retrieved26 May2022.
  8. ^Gupta, Ravindra K; Gregson, John; Parkin, Neil; Haile-Selassie, Hiwot; Tanuri, Amilcar; Andrade Forero, Liliana; Kaleebu, Pontiano; Watera, Christine; Aghokeng, Avelin; Mutenda, Nicholus; Dzangare, Janet (1 March 2018)."HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis".The Lancet Infectious Diseases.18(3): 346–355.doi:10.1016/S1473-3099(17)30702-8.ISSN1473-3099.PMC5835664.PMID29198909.
  9. ^Zanoni, Paolo; Khetarpal, Sumeet A.; Larach, Daniel B.; Hancock-Cerutti, William F.; Millar, John S.; Cuchel, Marina; DerOhannessian, Stephanie; Kontush, Anatol; Surendran, Praveen; Saleheen, Danish; Trompet, Stella (11 March 2016)."Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease".Science.351(6278): 1166–1171.Bibcode:2016Sci...351.1166Z.doi:10.1126/science.aad3517.ISSN0036-8075.PMC4889017.PMID26965621.
  10. ^Gregson, John; Tang, Michele; Ndembi, Nicaise; Hamers, Raph L; Rhee, Soo-Yon; Marconi, Vincent C; Diero, Lameck; Brooks, Katherine A; Theys, Kristof; Rinke de Wit, Tobias; Arruda, Monica (1 May 2016)."Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study".The Lancet Infectious Diseases.16(5): 565–575.doi:10.1016/S1473-3099(15)00536-8.ISSN1473-3099.PMC4835583.PMID26831472.
  11. ^Gurdasani, Deepti; Carstensen, Tommy; Tekola-Ayele, Fasil; Pagani, Luca; Tachmazidou, Ioanna; Hatzikotoulas, Konstantinos; Karthikeyan, Savita; Iles, Louise; Pollard, Martin O.; Choudhury, Ananyo; Ritchie, Graham R. S. (2015)."The African Genome Variation Project shapes medical genetics in Africa".Nature.517(7534): 327–332.Bibcode:2015Natur.517..327G.doi:10.1038/nature13997.ISSN1476-4687.PMC4297536.PMID25470054.S2CID4463627.
  12. ^Rhee, Soo-Yon; Blanco, Jose Luis; Jordan, Michael R.; Taylor, Jonathan; Lemey, Philippe; Varghese, Vici; Hamers, Raph L.; Bertagnolio, Silvia; Wit, Tobias F. Rinke de; Aghokeng, Avelin F.; Albert, Jan (7 April 2015)."Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis".PLOS Medicine.12(4): e1001810.doi:10.1371/journal.pmed.1001810.ISSN1549-1676.PMC4388826.PMID25849352.
  13. ^Nakimuli, Annettee; Chazara, Olympe; Hiby, Susan E.; Farrell, Lydia; Tukwasibwe, Stephen; Jayaraman, Jyothi; Traherne, James A.; Trowsdale, John; Colucci, Francesco; Lougee, Emma; Vaughan, Robert W. (20 January 2015)."A KIR B centromeric region present in Africans but not Europeans protects pregnant women from pre-eclampsia".Proceedings of the National Academy of Sciences.112(3): 845–850.Bibcode:2015PNAS..112..845N.doi:10.1073/pnas.1413453112.ISSN0027-8424.PMC4311823.PMID25561558.
  14. ^Zumla, Alimuddin; Chakaya, Jeremiah; Hoelscher, Michael; Ntoumi, Francine; Rustomjee, Roxana; Vilaplana, Cristina; Yeboah-Manu, Dorothy; Rasolofo, Voahangy; Munderi, Paula; Singh, Nalini; Aklillu, Eleni (2015)."Towards host-directed therapies for tuberculosis".Nature Reviews Drug Discovery.14(8): 511–512.doi:10.1038/nrd4696.ISSN1474-1784.PMID26184493.S2CID7418745.
  15. ^Adebamowo, Clement; Bah-Sow, Oumou; Binka, Fred; Bruzzone, Roberto; Caplan, Arthur; Delfraissy, Jean-François; Heymann, David; Horby, Peter; Kaleebu, Pontiano; Tamfum, Jean-Jacques Muyembe; Olliaro, Piero (18 October 2014)."Randomised controlled trials for Ebola: practical and ethical issues".The Lancet.384(9952): 1423–1424.doi:10.1016/S0140-6736(14)61734-7.ISSN0140-6736.PMC4392883.PMID25390318.
  16. ^Muyanja, Enoch; Ssemaganda, Aloysius; Ngauv, Pearline; Cubas, Rafael; Perrin, Helene; Srinivasan, Divya; Canderan, Glenda; Lawson, Benton; Kopycinski, Jakub; Graham, Amanda S.; Rowe, Dawne K. (1 July 2014)."Immune activation alters cellular and humoral responses to yellow fever 17D vaccine".The Journal of Clinical Investigation.124(7): 3147–3158.doi:10.1172/JCI75429.ISSN0021-9738.PMC4071376.PMID24911151.
  17. ^Nakimuli, Annettee; Chazara, Olympe; Byamugisha, Josaphat; Elliott, Alison M.; Kaleebu, Pontiano; Mirembe, Florence; Moffett, Ashley (1 June 2014)."Pregnancy, parturition and preeclampsia in women of African ancestry".American Journal of Obstetrics and Gynecology.210(6): 510–520.e1.doi:10.1016/j.ajog.2013.10.879.ISSN0002-9378.PMC4046649.PMID24184340.
  18. ^Consortium, Global Lipids Genetics (2013)."Discovery and refinement of loci associated with lipid levels".Nature Genetics.45(11): 1274–1283.doi:10.1038/ng.2797.ISSN1061-4036.PMC3838666.PMID24097068.
  19. ^Do, Ron; Willer, Cristen J.; Schmidt, Ellen M.; Sengupta, Sebanti; Gao, Chi; Peloso, Gina M.; Gustafsson, Stefan; Kanoni, Stavroula; Ganna, Andrea; Chen, Jin; Buchkovich, Martin L. (2013)."Common variants associated with plasma triglycerides and risk for coronary artery disease".Nature Genetics.45(11): 1345–1352.doi:10.1038/ng.2795.ISSN1546-1718.PMC3904346.PMID24097064.
  20. ^"Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis".International Journal of Epidemiology.Retrieved26 May2022.
  21. ^Seeley, Janet; Nakiyingi-Miiro, Jessica; Kamali, Anatoli; Mpendo, Juliet; Asiki, Gershim; Abaasa, Andrew; De Bont, Jan; Nielsen, Leslie; Kaleebu, Pontiano (2012)."High HIV Incidence and Socio-Behavioral Risk Patterns in Fishing Communities on the Shores of Lake Victoria, Uganda".Sexually Transmitted Diseases.39(6): 433–439.doi:10.1097/OLQ.0b013e318251555d.ISSN0148-5717.JSTOR44981712.PMID22592828.S2CID44811502.
  22. ^Asiki, Gershim; Mpendo, Juliet; Abaasa, Andrew; Agaba, Collins; Nanvubya, Annet; Nielsen, Leslie; Seeley, Janet; Kaleebu, Pontiano; Grosskurth, Heiner; Kamali, Anatoli (2011)."HIV and syphilis prevalence and associated risk factors among fishing communities of Lake Victoria, Uganda".Sexually Transmitted Infections.87(6): 511–515.doi:10.1136/sti.2010.046805.ISSN1472-3263.PMID21835763.S2CID332068.
  23. ^Price, Matt A.; Wallis, Carole L.; Lakhi, Shabir; Karita, Etienne; Kamali, Anatoli; Anzala, Omu; Sanders, Eduard J.; Bekker, Linda-Gail; Twesigye, Rogers; Hunter, Eric; Kaleebu, Pontiano (1 January 2011)."Transmitted HIV Type 1 Drug Resistance Among Individuals with Recent HIV Infection in East and Southern Africa".AIDS Research and Human Retroviruses.27(1): 5–12.doi:10.1089/aid.2010.0030.ISSN0889-2229.PMC3045073.PMID21091377.
  24. ^Karita, Etienne; Ketter, Nzeera; Price, Matt A.; Kayitenkore, Kayitesi; Kaleebu, Pontiano; Nanvubya, Annet; Anzala, Omu; Jaoko, Walter; Mutua, Gaudensia; Ruzagira, Eugene; Mulenga, Joseph (6 February 2009)."CLSI-Derived Hematology and Biochemistry Reference Intervals for Healthy Adults in Eastern and Southern Africa".PLOS ONE.4(2): e4401.Bibcode:2009PLoSO...4.4401K.doi:10.1371/journal.pone.0004401.ISSN1932-6203.PMC2632744.PMID19197365.
  25. ^Jaoko, Walter; Nakwagala, Frederick N.; Anzala, Omu; Manyonyi, Gloria Omosa; Birungi, Josephine; Nanvubya, Annet; Bashir, Farah; Bhatt, Kirana; Ogutu, Hilda; Wakasiaka, Sabina; Matu, Lucy (23 May 2008)."Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa".Vaccine.26(22): 2788–2795.doi:10.1016/j.vaccine.2008.02.071.ISSN0264-410X.PMID18440674.
  26. ^Kaleebu, Pontiano; Nankya, Immaculate L.; Yirrell, David L.; Shafer, Leigh Anne; Kyosiimire-Lugemwa, Jacqueline; Lule, Daniel B.; Morgan, Dilys; Beddows, Simon; Weber, Jonathan; Whitworth, James A. G. (1 May 2007)."Relation Between Chemokine Receptor Use, Disease Stage, and HIV-1 Subtypes A and D: Results From a Rural Ugandan Cohort".Journal of Acquired Immune Deficiency Syndromes.45(1): 28–33.doi:10.1097/QAI.0b013e3180385aa0.ISSN1525-4135.PMID17310935.S2CID11067305.
  27. ^Campbell, Grant R.; Pasquier, Eddy; Watkins, Jennifer; Bourgarel-Rey, Veronique; Peyrot, Vincent; Esquieu, Didier; Barbier, Pascale; Mareuil, Jean de; Braguer, Diane; Kaleebu, Pontiano; Yirrell, David L. (12 November 2004)."The Glutamine-rich Region of the HIV-1 Tat Protein Is Involved in T-cell Apoptosis *".Journal of Biological Chemistry.279(46): 48197–48204.doi:10.1074/jbc.M406195200.ISSN0021-9258.PMID15331610.
  28. ^Kaleebu, Pontiano; French, Neil; Mahe, Cedric; Yirrell, David; Watera, Christine; Lyagoba, Fred; Nakiyingi, Jessica; Rutebemberwa, Alleluiah; Morgan, Dilys; Weber, Jonathan; Gilks, Charles; Whitworth, Jimmy (2002)."Effect of Human Immunodeficiency Virus (HIV) Type 1 Envelope Subtypes A and D on Disease Progression in a Large Cohort of HIV-1—Positive Persons in Uganda".The Journal of Infectious Diseases.185(9): 1244–1250.doi:10.1086/340130.PMID12001041.
  29. ^Kaleebu, Pontiano; Ross, Amanda; Morgan, Dilys; Yirrell, David; Oram, Jon; Rutebemberwa, Alleluiah; Lyagoba, Fred; Hamilton, Laura; Biryahwaho, Benon; Whitworth, James (16 February 2001)."Relationship between HIV-1 Env subtypes A and D and disease progression in a rural Ugandan cohort".AIDS.15(3): 293–299.doi:10.1097/00002030-200102160-00001.ISSN0269-9370.PMID11273208.S2CID5761147.
  30. ^Weber, J; Fenyö, E M; Beddows, S; Kaleebu, P; Björndal, A (1996)."Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization".Journal of Virology.70(11): 7827–7832.doi:10.1128/jvi.70.11.7827-7832.1996.ISSN0022-538X.PMC190853.PMID8892904.
  31. ^Uganda Virus Research Institute."Kaleebu Receives Medal of Service on Labour Day".Uganda Virus Research Institute.Retrieved26 May2022.
[edit]
Political offices
Preceded by DirectorUganda Virus Research Institute
2016 - Present 		Succeeded by
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pontiano_Kaleebu&oldid=1243644627"